Rabi Dayal Singh* and Mangal Dayal Singh
Department of Pharmacology, Maulana Abul Kalam Azad University of Technology, India
*Corresponding Author: Rabi Dayal Singh, Department of Pharmacology, Maulana Abul Kalam Azad University of Technology, India.
Received: May 04, 2020; Published: May 31, 2020
COVID-19 has as of late caused a worldwide wellbeing emergency and a powerful interventional treatment is earnestly needed . SARS-CoV-2 RNA-subordinate RNA polymerase (RdRp) gives a promising however testing drug focus because of its inherent editing exoribonuclease (ExoN) function . Nucleoside triphosphate (NTP) analogs added to the developing RNA chain ought to as far as anyone knows end viral RNA replication, yet ExoN can divide the fused mixes and neutralize their viability. Remdesivir focusing on SARS-CoV-2 RdRp applies high medication viability in vitro and in vivo .
Citation: Rabi Dayal Singh and Mangal Dayal Singh. “Remdesivir as Reposition Drugs for Novel Coronavirus SARS-COV-2 Emergence". Acta Scientific Medical Sciences 4.6 (2020): 147-148.
Copyright: © 2020 Rabi Dayal Singh and Mangal Dayal Singh. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.